Aurinia Pharmaceuticals Inc. Stock Toronto S.E.
Equities
AUP
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 227M 310M | Sales 2025 * | 282M 385M | Capitalization | 742M 1.01B |
---|---|---|---|---|---|
Net income 2024 * | 9M 12.27M | Net income 2025 * | 71M 96.8M | EV / Sales 2024 * | 1.53 x |
Net cash position 2024 * | 395M 539M | Net cash position 2025 * | 448M 610M | EV / Sales 2025 * | 1.04 x |
P/E ratio 2024 * |
89.7
x | P/E ratio 2025 * |
11
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.47% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
1st Jan change | Capi. | |
---|---|---|
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.46% | 21.25B | |
-5.89% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |